Sunnyvale, CA – December 7, 2021 – Gener8 LLC (“Gener8”), a portfolio company of Sverica Capital Management LP (“Sverica”), announced today that it has completed its acquisition of the RND Group (“RND”), a leading provider of software development focused on medical device and life science products, based in Indianapolis, Indiana.
With the acquisition of RND, Gener8 is adding full lifecycle software development capabilities, including cloud solutions, verification & validation, quality system compliance, LIS/EHR integration and more. The company has assembled a library of protocols that serve to accelerate the development process by leveraging pre-built core functionality. While Gener8 already provides turnkey instrument and consumable solutions, as well as accompanying firmware, the acquisition of RND enables Gener8 to extend its services off-instrument to the related software.
“RND is a world-class medical software development operation with a blue-chip customer base and a unique set of capabilities,” said Jerry Jurkiewicz, Gener8 CEO. “We have already partnered on several programs, and the value proposition of the combination has strongly resonated with customers.”
“We are excited to join Jerry and the rest of the Gener8 team. From our early interactions it was clear there would be a great fit between our companies, and even more importantly, that bringing our capabilities together under one roof would be a real winner for customers,” added Tim DeFrench, Founder and President of RND.
Gener8, founded in 2002, is a leading provider of turnkey design and manufacturing services specializing in high complexity products, primarily for medical device and diagnostics applications. Gener8 maintains state-of-the-art facilities and a world-class engineering team with more than 40 PhDs spanning a multitude of disciplines, including electrical, mechanical, software, optical and systems engineering. For more information, please visit www.gener8.net.